NCT00095160已完成1 期
Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Safety and Pharmacokinetics
研究概览
简要总结
Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of the study is to monitor the tumor response to this form of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have solid organ tumors refractory to currently available treatments.
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
- •Have a life expectancy of 4 months
- •Have normal organ and bone marrow function
排除标准
- •Have had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy within 4 weeks prior to the 1st dose of the study drug or those who have not recovered from adverse events from agents administered more than 4 weeks earlier.
- •Use of investigational agent in the 4 weeks prior to 1st dose of the study drug
- •Use of immunosuppressive therapy in the 4 weeks prior to the 1st dose
- •Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months
- •Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements
- •Have a history of disease requiring ongoing steroid treatment
- •Have a history of seizure disorders uncontrolled on medication
- •Have a history of clinically significant coagulation or bleeding disorders or abnormalities
- •Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.
- •Are pregnant or lactating
结局指标
主要结局
Safety and Pharmacokinetics
次要结局
- Tumor Response
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseMyelofibrosisNCT02436135Gilead Sciences10
招募中
1 期
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C MutationAdvanced Solid TumorsNCT05768321GenEros Biopharma Hangzhou Ltd70
已完成
1 期
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced MalignanciesNeoplasmsNCT02485119Bayer12
终止
1 期
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsOvarian CancerGastric CancerBreast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast CarcinomaHer2-PositiveHER2 Gene MutationGastroesophageal-junction CancerNon Small Cell Lung CancerEndometrial NeoplasmsPeritoneal CancerFallopian Tube CancerUrothelial Carcinoma BladderSolid Tumor, AdultNCT06714617SystImmune Inc.3
已完成
1 期
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)Fallopian Tube CancerPeritoneal CancerAdvanced Solid Tumor With Evidence of Germline or Somatic BRCAOvarian CancerNCT01482715pharmaand GmbH136